Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease

Figure 1 Glycemic control and body weight in patients enrolled in the study and included in groups treated with the sodium-glucose co-transporter-2 inhibitors or other glucose-lowering drugs before (T0) and after 1 wk of treatment (T1). A: Serum fasting glucose; B: Serum hemoglobin A1c; C: Serum triglycerides; D: Body mass index in patients observed in the study, grouped according to the assigned treatment. Data in the graphs are represented as mean ± SEM. Two-way analysis of variance and Tukey assessed statistical differences as post hoc test. ^aP < 0.05, ^bP < 0.001. HbA1c: Hemoglobin A1c; SGLT2-I: Sodium-glucose co-transporter-2 inhibitor; OTHER: Other glucose lowering drug; BMI: Body mass index.